DEMENTIA

Association Between Blood Pressure Variability With Dementia and Cognitive Impairment: A Systematic Review and Meta-Analysis

Rianne A.A. de Heus, Christophe Tzourio, Emily Jo Lynn Lee, Melissa Opozda, Andrew D. Vincent, Kaarin J. Anstey, Albert Hofman, Kazuomi Kario, Simona Lattanzi, Lenore J. Launer, Yuan Ma, Rajiv Mahajan, Simon P. Mooijaart, Michiaki Nagai, Ruth Peters, Deborah Turnbull, Yuichiro Yano; the VARIABLE BRAIN Consortium; Jurgen A.H.R. Claassen, Phillip J. Tully

ABSTRACT: Research links high blood pressure variability (BPV) with stroke and cerebrovascular disease, however, its association with cognition remains unclear. Moreover, it remains uncertain which BP-derived parameter (ie, variability or mean) holds more significance in understanding vascular contributions to cognitive impairment. We searched PubMed, Embase, PsycINFO, and Scopus and performed a meta-analysis of studies that quantified the association between resting BPV with dementia or cognitive impairment in adults. Two authors independently reviewed all titles, abstracts, and full-texts and extracted data, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses and Meta-Analysis of Observational Studies in Epidemiology guidelines. Study quality was assessed using the (modified) Newcastle-Ottawa Scale. A multilevel meta-analysis was used, which included effect sizes for both BPV and mean BP, with a combined end point of dementia or cognitive impairment as primary outcome. In the primary analysis, 54 effect sizes were extracted from 20 studies, with a total analytical sample of n=7,899,697. Higher systolic BPV (odds ratio [OR], 1.25 [95% CI, 1.16–1.35]), mean systolic pressure (OR, 1.12 [95% CI, 1.02–1.29]), diastolic BPV (OR, 1.20 [95% CI, 1.12–1.29]), and mean diastolic pressure (OR, 1.16 [95% CI, 1.04–1.29]) were associated with dementia and cognitive impairment. A direct comparison showed that mean BP effect sizes were less strong than BPV effect sizes (OR, 0.92 [95% CI, 0.87–0.97], P<0.01), indicating that the relative contribution of BPV exceeded that of mean BP. Methodological and statistical heterogeneity was high. Secondary analyses were less consistent as to whether BPV and mean BP were differentially associated with dementia subtypes and cognitive domains. Future studies are required to investigate BPV as a target for dementia prevention. (Hypertension. 2021;78:1478–1489. DOI: 10.1161/HYPERTENSIONAHA.121.17797.) • Data Supplement

Key Words: Alzheimer disease ■ blood pressure ■ cerebrovascular disorders ■ dementia ■ hemodynamics ■ meta-analysis ■ stroke

High blood pressure (BP) during mid-life is widely recognized as a modifiable risk factor for late-life dementia.1,2 Subsequently, lowering high BP with antihypertensive medication during mid-life is a recommended strategy to prevent dementia.3,4 Yet, several uncertainties remain that hamper clinical guidelines for the management of BP to maintain brain health, including optimal BP targets in mid- to late-life and the choice of antihypertensive drug(s).5 The inconsistency in findings raises the possibility that BP-related factors beyond absolute BP level or treat-to-target BP could be important for dementia prevention and early intervention.

A body of empirical work indicates that oscillations in BP between consecutive measures hold additional prognostic significance, alongside mean BP level, for the risk of cardiovascular diseases and subclinical target
organ damage.\textsuperscript{6,7} Previous meta-analyses have reported associations of high BP variability (BPV) with stroke and cerebral small vessel disease (CSVD), underscoring the importance of BPV to brain health.\textsuperscript{8–10} An association between BPV with dementia and cognitive impairment was reported as part of a larger meta-analysis on BP and cognition but was limited to only 2 studies.\textsuperscript{11}

Evaluating the current evidence regarding BPV and cognitive function may inform evidence-based clinical practice regarding BP management to preserve brain health. Therefore, the objective of this review is to quantify the association between intraindividual BPV with the risk of dementia or cognitive impairment. A second objective is to compare the magnitude of the association between BPV and cognitive outcomes with the effect sizes for mean BP.

METHODS

The authors declare that all supporting data are available within the article and its Data Supplement. The protocol of this systematic review was registered with the International Prospective Register of Systematic Reviews (CRD42017081977) and published.\textsuperscript{12} The study followed the Meta-Analysis of Observational Studies in Epidemiology and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.\textsuperscript{13,14}

Sources and Search Strategy

A comprehensive search of PubMed (Medline), Embase, PsycINFO, and Scopus without language restriction was performed from database inception to April 20, 2021 (Data Supplement). Two reviewers (R.A.A. de Heus and M. Opozda) independently screened titles and abstracts to assess eligibility. Full text was evaluated if eligibility was not clear from the abstract. Inconsistencies were resolved by consulting a third reviewer (P.J. Tully). Articles and conference abstracts of case-control studies, prospective cohorts, database registries, cross-sectional studies, and (secondary analyses of) randomized controlled trials were eligible for inclusion. A hand-search was performed of the articles selected for full-text review and of narrative reviews,\textsuperscript{15,16} supplementing the electronic search. Where necessary, we contacted authors of relevant articles to request additional data.

Eligibility Criteria

Studies were considered eligible if they investigated an adult sample (≥18 years), examined BPV using repeated measurements of BP at rest, assessed a prespecified cognitive outcome (see below), and reported the association between BPV and study outcome(s), or could provide additional analyses. No restriction was placed on sample size or length of follow-up. Reporting the association between mean BP and study outcome(s) was not a prespecified inclusion criterion. Because the field is lacking a gold standard for quantifying intraindividual BPV, all common metrics were eligible, prioritizing the coefficient of variation where studies reported multiple metrics (Data Supplement).\textsuperscript{17} Studies including persons with baseline dementia were excluded if they did not report the association of BPV with cognition separately for those without dementia. Studies in patients with recent stroke, Parkinson disease, receiving hemodialysis or renal denervation, revascularization, or facing orthostatic challenge were ineligible.

Outcomes

The primary outcome was the odds for dementia or cognitive impairment attributable to BPV or mean BP. Studies that reported incident dementia, cognitive impairment, a composite of dementia or cognitive impairment, or compared dementia and nondementia groups were included. This approach was chosen to maximize the number of studies in the primary analysis and because dementia and cognitive impairment

| Nonstandard Abbreviations and Acronyms |
|---------------------------------------|
| BP (blood pressure)                   |
| CSVD (cerebral small vessel disease)   |
| GRADE (Grading of Recommendations Assessment, Development and Evaluation) |
| OR (odds ratio)                       |

**Novelty and Significance**

**What Is New?**
- High blood pressure variability may be a predictor for the risk of dementia or cognitive impairment.
- The relative contribution of variability in blood pressure exceeded that of mean blood pressure.

**What Is Relevant?**
- Variability might be a novel blood pressure-derived parameter to be taken into account in hypertension management.
- Blood pressure variability might be a future target to prevent dementia.

**Summary**

In this meta-analysis, that included 20 studies for the primary outcome, both a higher mean level of blood pressure as well as a higher degree of blood pressure variability were associated with greater odds for dementia or cognitive impairment. Effect sizes for blood pressure variability were larger than effect sizes for mean blood pressure.
represent a continuum of the same syndrome. The definition of dementia was criterion-referenced and was based on International Classification of Disease criteria, Diagnostic and Statistical Manual of Mental Disorders criteria, an adjudicated expert panel or the prescription of antidementia drugs, inclusive of any dementia, Alzheimer disease, Vascular dementia, or mixed cause. The definition of cognitive impairment was any of the following definitions that were standardized within studies: criterion-referenced diagnosis of mild cognitive impairment,\(^16,17\) a cognitive test score below a predefined, clinical cutoff point, a predefined between-assessment decline, or a score below age and sex appropriate normative data, all based on standardized tests of global cognitive function or assessing specific cognitive domains. Studies using self-reported measures were ineligible.

The secondary outcomes were other effect sizes reporting on the association between BPV and cognition. This included (standardized) mean cognitive function scores in the lowest versus highest group of BPV or mean BP (eg, quartiles) and conversely (standardized) mean differences in BPV and mean BP when grouped by cognitive function. Furthermore, effect sizes of \(\mu/r\) family reporting the correlation between BPV and cognition on a continuous scale were extracted for analyses.

**Data Extraction**

Data were independently extracted by 3 reviewers (R.A.A. de Heus, M. Opozda, and E.J.L. Lee) and verified by a fourth reviewer (P.J. Tully). We extracted information pertaining to study identification (first author, year, country, and study name), design characteristics (design, population, sample size, and follow-up), population characteristics (age, sex, education, use of antihypertensive medication, and comorbidities), characteristics of BP(V) (measurements, timing, interval, setting, device, and metrics), dementia adjudication (criteria, subtypes, consensus panel, and number of end points), cognitive testing (tests used, domains assessed, and criteria for impairment or decline), effect sizes (most adjusted effect sizes), and list of adjusted covariates. When studies reported multiple metrics of BPV, we prioritized the methods that adjusted for mean BP level (eg, coefficient of variation instead of SD). The association of mean BP with study outcomes was extracted when available. Effect sizes of mean BP for dementia or cognitive impairment were standardized to 10/5 mm Hg increase as not all studies reported the SD of mean BP. In instances where different levels of adjustment were made for mean and BPV data, we prioritized data from the same model to ensure equivalence in covariate adjustment.

**Quality Assessment**

The risk of bias within each study was assessed independently by 2 reviewers (R.A.A. de Heus and M. Opozda) using modified versions of the Newcastle-Ottawa Scale, for cross-sectional, case-control, and cohort designs.\(^20\) Discrepancies were resolved by consulting a third reviewer (P.J. Tully). Adjudication of the strength of evidence for the hypothesis that high BPV increases the risk for dementia or cognitive impairment was made according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria, with GRADE Profiler 3.6.1.\(^21\)

**Deviations From Protocol**

Based on preliminary data extraction and performing a parallel review on BPV and CSVD, several changes were instigated from the published protocol.\(^10,12\) Our adjudication of the primary outcome was expanded, combining dementia and cognitive impairment together, opting to analyze the categories separately in ancillary analysis. Second, we included cross-sectional studies to estimate the association between BPV with dementia or cognitive impairment, opting to analyze different study designs separately in ancillary analysis. Also, we excluded studies assessing beat-to-beat BPV, as this metric likely represents a different physiological mechanism compared with 24-hour, day-to-day, and visit-to-visit BPV.\(^22,23\)

**Statistical Analysis**

Data pertaining to the likelihood of dementia or cognitive impairment were pooled as odds ratio (OR) with 95% CIs. A multilevel meta-analysis was used using the metafor package in R version 3.5.2.\(^24\) Compared with a traditional meta-analysis, a multilevel meta-analysis accounts for the dependence in effect sizes within a study (eg, between BPV and mean BP from which BPV is often calculated; and dependence of systolic and diastolic BP).\(^10\) Thus a single study could contribute up to 4 effect sizes for each analysis (systolic BP and BPV, diastolic BP and BPV). A mixed-effects model, with a random intercept per study, tested fixed effect moderators for BP type (diastolic versus systolic) and measure (mean versus variability). Random-effects models (inverse-variance method) were used under the assumption of high sampling variability between studies, different BPV metrics, and cognitive function outcomes.\(^25\) Statistical heterogeneity was evaluated with the \(I^2\) statistic and methodological heterogeneity was explored with meta-regression in Comprehensive Meta-Analysis software.\(^26\) The presence of publication bias was evaluated with the test of Egger,\(^27\) Begg-Mazumdar,\(^28\) and the Duval and Tweedie trim-and-fill funnel plot.\(^29\)

Separate analyses considered key methodological and descriptive characteristics that might modulate the association between BP and dementia cognitive impairment and the different dementia subtypes (Data Supplement). The standardized mean difference between groups of BPV or cognitive impairment groups (dementia or impairment versus no dementia or impairment) were modeled with RevMan 5.3, analyzing cognitive function or BPV, respectively.\(^26\) Comprehensive Meta-Analysis software was used for the analysis of \(r\) family effect sizes showing the linear association between BP(V) measures and cognitive function.\(^26,31\)

**RESULTS**

**Study Selection and Characteristics**

After duplicate removal, 2661 records were screened, from which 53 were retained (Figure 1). Reasons for exclusion after full-text review are described in Table S1 in the Data Supplement.\(^32-61\) Twenty unique studies samples met the inclusion criteria for the primary outcome (analytical n=7 899 679).\(^52-71\) These comprised 8 cohort studies (n=18 067), 2 nested cohort studies (n=698),

\[ \text{Hypertension. 2021;78:1478–1489. DOI: 10.1161/HYPERTENSIONAHA.121.17797} \]
Eleven studies assessed visit-to-visit office BPV, 4 studies 24-hour ambulatory BPV, 4 studies day-to-day home BPV, and 1 study intravisit office BPV. Characteristics are presented in the Table and additional information in Tables S2 through S4.

Forty-seven records, comprising 43 unique study samples (analytical n=7,915,946) reported any of the secondary outcomes. Seventeen studies reported standardized mean difference in BPV between groups of cognitive function, 17 studies reported standardized mean difference in cognitive function between groups of BPV, and 23 studies reported the linear association between BPV with cognitive function. Characteristics are presented in Tables S4 and S5.

Study Quality and GRADE Rating

Quality assessment is presented in Tables S6 through S8. Overall quality was deemed good in 16 studies, fair in one study and poor in 3 studies. In all studies, BP was assessed with reliable methods. Eight studies did not adjust their analyses of BPV for mean BP. There was evidence of publication bias for systolic BPV, based on funnel plot asymmetry and Egger test (P=0.023; Table S9 and Figure S1). GRADE rating of the quality of evidence was very low (Table S10).

BPV and Dementia or Cognitive Impairment

Fifty-four effect sizes retrieved from 20 studies were included in the multilevel model (Figure 3). The model included 21 systolic BPV, 11 mean systolic BP, 15 diastolic BPV, and 7 mean diastolic BP effect sizes. Higher systolic BPV was significantly associated with an increase in dementia/cognitive impairment (OR, 1.25 [95% CI, 1.16–1.35]; I²=87%), as was mean systolic BP (OR, 1.12 [95% CI, 1.02–1.29]; P=82%). Similar results were found for diastolic BPV (OR, 1.20 [95% CI, 1.12–1.29]; P=83%) and mean diastolic BP (OR, 1.16 [95% CI, 1.04–1.29]; P=3%). When effect sizes were directly compared in the multilevel meta-analysis, the association of mean BP with the primary outcome was less strong compared with the association of BPV with the primary outcome (OR, 0.92 [95% CI, 0.87–0.97]; P<0.01 for comparison). Diastolic effect sizes were also less strong than systolic effect sizes in a direct comparison including both BPV and mean BP (OR, 0.96 [95% CI, 0.95–0.98]; P<0.001 for comparison). Overall, heterogeneity was high.

Meta-Regression and Subgroup Analyses

Results of the meta-regression on the primary outcomes are presented in Table S11. Higher mean BP of the study population was associated with an attenuation in association, and thus lower effect sizes, for both systolic
BPV (coefficient, −0.003 [95% CI, −0.005 to −0.001]) and diastolic BPV (coefficient, −0.030 [95% CI, −0.039 to −0.021]; Figure 4). In addition, effect sizes for BPV were associated with lower age, female sex, low education, shorter interval between consecutive BP measures, shorter total interval of BP measurements, lower body mass index, and diabetes.

Subgroup analyses by methodological characteristics are presented in Figures S2 and S3. Systolic BPV analyses indicated heterogeneity for study quality, follow-up length, BP measurement (oscillometric versus other), BP measurement interval, and study region. Studies including only patients with hypertension were heterogenous for systolic BPV compared with other studies. For diastolic BPV, there was evidence of heterogeneity between study designs and type of BPV metric.

The analysis stratified by subtypes of the primary outcome supported the main findings, indicating an association between BPV and risk of dementia (any type), Alzheimer disease, vascular dementia, cognitive

Figure 2. Schematic overview of included studies for the primary analysis.

X axis represents time in years and each study is presented at the mean age of the study population at baseline. Chuang et al (2016) and Matsumoto et al (2018) are missing from this overview because these studies (abstract only) did not report the mean age of the study population. A indicates ambulatory blood pressure measurements (24-h); H, home blood pressure measurements; S, single-visit (within-visit BP variability); and V, visit-to-visit variability (number presents number of visits).
impaired, and cognitive decline (Figure S4). However, the main finding of stronger effect sizes for BPV compared with mean BP was not supported in these subtypes, with the exception of Alzheimer disease ($P<0.01$).

Secondary Outcomes

Results of the secondary outcomes analyses were generally consistent with the primary outcome analysis (Figures S5–S7), although evidence was sparse. Comparing BP(V) between groups of cognitive function indicated higher systolic BPV in those with cognitive impairment, with no difference observed for mean BP. Conversely, we observed lower general cognitive function in those with high BPV compared with low BPV. In addition, general cognitive function and BPV were associated in studies reporting $\beta/r$ effect sizes, although for diastolic BPV this was only a trend. Associations between cognition and mean BP in secondary analyses were inconsistent, with mean systolic BP associated with improved memory and attention/executive/psychomotor indices.

### Table. Characteristics of Included Studies for the Primary Analysis

| First author | Year | Country | Name of study | Design | Study sample | Sample size | Primary outcome criteria | Type of BP measurement | Length of follow-up |
|--------------|------|---------|---------------|--------|--------------|-------------|-------------------------|-----------------------|------------------|
| Matsumoto61* | 2014 | Japan   | Ohasama Cohort | General population (55+) | 5273 | DSM-III-R criteria, expert panel | Visit-to-visit | 14.8 y (MED) |
| Ma60          | 2019 | The Netherlands | Rotterdam Cohort | General population (55+) | 485 | MMSE <24 at follow-up | Visit-to-visit | 7.8 y (MED) |
| Matsumoto62  | 2018 | Japan   | JPAD2 RCT | Patients with diabetes (30-85) | 2450 | Prescription of antide-mentia drugs or dementia admission | Visit-to-visit | 9 y |
| McDonald63    | 2017 | England | NA Cohort | Community-dwelling elderly (65+) | 302 | change in MMSE after 5 y | 24-h ABPM | 5 y |
| Nagai64       | 2012 | Japan   | Shobara City Soryo Town Nested cohort | Outpatients with CVD factor(s) (70+) | 201 | MMSE <24 | Visit-to-visit | 3 mo |
| Oishi65       | 2017 | Japan   | Hisayama Cohort | General population (60+) | 1674 | DSM-III criteria, expert panel | Day-to-day | 5 y |
| Peters66†     | 2008 | Multi-national | HYVET-COG RCT | Hypertensive elderly (80+) | 3336 | DSM-IV criteria, expert panel | Visit-to-visit | 2.2 y (M) |
| Rouch67       | 2019 | France  | SAGES Cohort | Community-dwelling elderly (65+) | 3319 | DSM-IV criteria | Visit-to-visit | 2.6 y (M) |
| Sakakura68    | 2007 | Japan   | NA Cross-sectional | Outpatients with chronic diseases (60+) | 202 | lowest tertile of MMSE | 24-h ABPM | ... |
| van Middelaar69,70 | 2018 and 2016 | The Netherlands | Pre-DIVA RCT | Community-dwelling elderly | 2305 | DSM-IV criteria, expert panel | Visit-to-visit | 6.4 y (M) |
| Yamaguchi70   | 2014 | Japan   | NA Cohort | General population (70–72) | 188 | ≥1 point MMSE decrease after 4 y | 24-h ABPM | 4 y |
| Yoo71         | 2020 | Korea   | Korean NHIS | Retrospective registry | 7844814 | ICD codes/prescription of antidementia drugs | Visit-to-visit | 6.2 y (MED) |

ABPM, ambulatory blood pressure monitoring; AD, Alzheimer disease; BPV, blood pressure variability; CVD, cardiovascular disease; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD, International Classification of Diseases; M, mean; MED, median; MMSE, Mini-Mental State Examination; NA, not applicable; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; and RCT, randomized controlled trial.

*Conference abstract only. Additional information for quality assessment was retrieved from Ogawa et al73 (2008), Chuang et al74 2013, and Matsumoto et al75 2020.
†Authors performed additional analysis on request.
DISCUSSION

This systematic review and meta-analysis showed that elevated BPV is associated with a higher risk of dementia and cognitive impairment. Findings were generally consistent across dementia subtypes and general cognitive impairment, although published data were sparse for secondary outcomes. These findings are derived from observational studies of generally good quality but with high heterogeneity and evidence of publication bias in the retained articles. As such, the GRADE rating and strength of evidence were very low for the primary outcome, which tempers the conclusions that can be drawn.

Our findings emerge in the context of past research documenting associations between cognitive function and impaired BP regulation, such as circadian variation and orthostatic hypotension\(^9\),\(^{10}\) as well as previous systematic reviews relating BPV to neurological outcomes, including acute stroke, transient ischemic attack, CSVD, and dementia.\(^8\)\(^{11}\) Here, multilevel meta-analysis modeling demonstrated that dementia and cognitive impairment were more consistently associated with BPV than with mean BP. This contrasts with our previous finding showing BPV contributes to CSVD risk but no more than mean BP.\(^10\) Besides methodological differences, this discrepancy can be partly explained by the timing of BP variability, which affects the risk of cognitive decline.
and outcome assessment. CSVD is known to be primarily induced by hypertension, whereas the link between cardiovascular risk and cognitive impairment is strongest in mid-life, becoming more ambiguous at late-life. In addition, it is likely that the association between BPV and cognitive impairment is only partly attributable to CSVD, involving other pathways such as Alzheimer pathology, hypoxia and blood-brain barrier dysfunction. Conversely, neurodegeneration in brain regions involved in autonomic control might lead to high BPV, as indicated by heterogeneity in effect sizes for diastolic but not systolic BPV when study designs were compared. However, this is not supported by evidence demonstrating intact baroreflex function in early dementia, hinting towards normal BP regulation. Indeed, definitive answers on the direction of causality between BP regulation and dementia are currently lacking.

Our review analyzed an extensive spectrum of cognitive outcomes. There were sparse published data for vascular dementia, mixed dementia, cognitive decline, and domain-specific cognitive function. As such, the association between BPV and secondary outcomes was less clear. The putative association between BP with dementia appears strongest for vascular dementia often as a result of cerebrovascular disease. Yet brain imaging studies indicate that the majority of dementia cases, including Alzheimer disease, have a mix of neurodegenerative and vascular-type pathology evident (e.g., amyloid-β, lacunes of vascular origin). The combination of neurodegenerative and vascular pathologies further underscores how BP only partly explains the neurodegenerative processes preceding dementia and that BP may work in concert with other nonvascular and vascular risk factors. Previously, we raised the possibility that the interaction between BPV and white matter hyperintensities leads to impairments in processing speed and executive function, with BPV especially impacting periventricular white matter pathways.

The lack of consensus on BPV measurement and quantification contributes substantial heterogeneity between studies. Different BPV metrics were pooled separately in ancillary analyses and demonstrated generally consistent results. Likewise, there was no evidence of heterogeneity between intravisit, 24-hour ambulatory BP monitoring, home BP, and visit-to-visit variability. BP measurement intervals of 6 months or less conferred a higher risk for the primary outcome than did BP intervals greater than 6 months. Long-term BPV are hypothesized to both reflect arterial reflex and compliance and dosing/titration of antihypertensive medications. Previously meta-analytic findings indicate that both short- and long-term BPV are associated with cardiovascular outcomes and mortality.

Strengths of this study include the multilevel approach, the large pooled analytical sample, and extensive ancillary analyses. Several limitations temper the results of this review including evidence of publication bias. The retained studies were primarily undertaken in older aged adults (mean age 55–84 years) which may explain the difference in effect sizes observed for BPV and mean BP. Inclusion of such wide-ranging age groups may introduce other biases in the analyses, such as selection and attrition bias. In addition, our review was marked by significant heterogeneity even when limiting analyses to high-quality studies, implicating methodological and population characteristics as a source of between-study heterogeneity.

Another limitation is that several studies defined visit-to-visit BPV using BP measurements that were taken during follow-up, introducing bias due to informative censoring. Likewise, some studies adjusted BP analyses for mean BP which may lead to an attenuation of effect sizes due to over-adjustment or multicollinearity. These are inherent limitations of the original studies, which were not designed to prospectively assess BPV independent of mean BP. Pooled analyses are prone to aggregation of study-level biases, and therefore, an individual participant data meta-analysis might reduce methodological heterogeneity and offer new insights on the role of BPV in dementia risk.

**Perspectives**

In summary, this systematic review and meta-analysis showed that high BPV was associated with an increased risk of dementia and cognitive impairment, although the strength of evidence was low. The relative contribution of BPV to the risk of dementia and cognitive impairment exceeded that of mean BP in primarily older adult samples. Further investigation is warranted concerning the mechanisms through which BPV may confer heightened dementia risk over mean BP, and the potential of BPV as a target for dementia prevention.

**ARTICLE INFORMATION**

Received June 3, 2021; accepted August 4, 2021.

**Affiliations**

Radboud University Medical Center, Department of Geriatric Medicine, Radboudumc, Alzheimer Center, Donders Institute for Brain, Cognition, and Behaviour, Nijmegen, the Netherlands (R.A.A.d.H., J.A.H.R.C.). Bordeaux Population Health, University of Bordeaux, Inserm, Team Healthy, UMR 1219, CHU Bordeaux, France (C.T.). Adelaide Medical School (E.J.L.L., M.O., A.D.V., P.J.T.) and School of Psychology (D.T.), Freemasons Centre for Male Health and Wellbeing, The University of Adelaide, Australia. Centre for Nutrition and Gastrointestinal Research (M.O.) and University of Adelaide, Lyell McEwin Hospital (R.M.), South Australian Health and Medical Research Institute, Australia. School of Psychology (K.J.A.), Neuroscience Research Australia (K.J.A.), and Neuroscience Research Australia (RP), University of New South Wales, Sydney, Australia. Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, MA (AH, YM). Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan (KK). Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy (SL). Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, MD (L.J.L.). Department of Gerontology and Geriatrics, Leiden University Medical Center, Institute for Evidence-Based Medicine.
REFERENCES

1. Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–794. doi: 10.1016/S1474-4422(14)70136-X

2. Whittmer RA, Siddiqi S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–281. doi: 10.1212/01.WNL.0000149519.47454.F2

3. Livingston G, Hunter J, Sommerland A, Ames D, Ballard C, Banerjee S, Brayne C, Burns C, Cohen-Mansfield J, Cooper C, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:143–446. doi: 10.1016/S0140-6736(20)30867-6

4. Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, Bosch J, O’Donnell MJ, Canavan M. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020;323:1934–1944. doi: 10.1001/jama.2020.4249

5. Iadecola C, Gottfries RF. Neurovascular and cognitive dysfunction in hypertension. Curr Res. 2019;124:1025–1044. doi: 10.1161/CIRCRESAHA.118.313260

6. Rothwell PM. Limitations of the usual blood-pressure measures and importance of variability, instability, and episodic hypertension. Lancet 2010;375:928–949. doi: 10.1016/S0140-6736(10)60390-1

7. Stevens SL, Wood S, Kossharisl C, Law K, Glasziou P, Stevens RJ, McManus RJ. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ. 2016;354:i4098. doi: 10.1136/bmj.i4098

8. Wang H, Li M, Xie SH, Oyang YT, Yin M, Bao B, Chen ZY, Yin XP. Visit-to-visit systolic blood pressure variability and stroke risk: a systematic review and meta-analysis. J Hypertens. 2019;37:741–747. doi: 10.1093/hypertension/haz156

9. Ma Y, Song A, Viswanathan A, Blacker D, Visscher M. Visit-to-visit blood pressure variability and dementia: a systematic review and meta-analysis. Eur J Neurol. 2014;21:134–144. doi: 10.1111/1468-1331.12588

10. De Heus et al. BP Variability and Cognitive Impairment

11. Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, Tan L, Yu JT. Blood pressure variability and cardiovascular outcomes: a systematic review and meta-analysis. Front Physiol. 2020;11:524. doi: 10.3389/fphys.2020.00524

12. VARIABLE BRAIN consortium. The association between blood pressure variability (BPV) with dementia and cognitive function: a systematic review and meta-analytical protocol. Syst Rev. 2018;7:163. doi: 10.1186/s13643-018-0811-9

13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008

14. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535

15. Nagai M, Hoshide S, Dote K, Kario K. Visit-to-visit blood pressure variability and dementia. Geriatr Gerontol Int. 2015;15(Suppl 1):26–33. doi: 10.1111/ggi.12660

16. Ma Y, Tully PJ, Hofman A, Tzourio C. Blood pressure variability and dementia: a state-of-the-art review. Am J Hypertens. 2020;33:1059–1066. doi: 10.1093/ajh/hpaa119

17. Stergiou GS, Parati G, Vlachopoulos C, Achimastos A, Andreidis E, Asmar R, Avolio A, Benetos A, Bilo G, Bouchouairopoulou N, et al. Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions - position statement of the European Society of Hypertension working group on blood pressure monitoring and cardiovascular variability. J Hypertens. 2016;34:1665–1677. doi: 10.1093/hypertens/hjw009

18. Albert MS, DeCosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from The National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7:270–279. doi: 10.1016/j.jalz.2011.03.008

19. Petersen RC, Caraccio B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Int Med Res. 2014;42:2174–228. doi: 10.1177/0300060514551055

20. Wells G, Shea B, O’Connor D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis. Accessed July 20, 2021. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

21. Schunemann H, Brozek J, Guyatt G, Oxman A. editors: The GRADE Working Group. GRADEPRO GD: GRADEPro Guideline Development Tool [Software]. McMaster University, Hamilton, Ontario 2020. wwwGRADEpro.org.

22. Rickards CA, Tzeng YC. Arterial pressure and cerebral blood flow variability: friend or foe? A review. Front Physiol 2014;5:120. doi: 10.3389/fphys.2014.00120

23. Ma Y, Zhou J, Kavousi M, Lipsitz LA, Mattace-Raso F, Westerhoff BE, Wolters FJ, Wu JW, Manor B, Ikram MK, et al. Lower complexity and higher variability in beat-to-beat systolic blood pressure are associated with elevated long-term risk of dementia; The Rotterdam Study. Alzheimers Dement. 2021;17:134–144. doi: 10.1002/alz.12288

24. Assink M, Wabbelink CJM. Fitting three-level meta-analytic models in r: a step-by-step tutorial. Quant Meth Psychol 2016;12:154–174

25. Taylor KS, Heneghan CJ, Stevens RJ, Adams EC, Nunan D, Ward A. Heterogeneity of prognostic studies of 24-hour blood pressure variability: systematic review and meta-analysis. PLoS One 2015;10:e0126375. doi: 10.1371/journal.pone.0126375

26. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version 2 Bostons Englewood, NJ 2011

27. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629

28. Beggg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101

29. Duval S, Tweedie R. Trim and fill: a funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–463. doi: 10.1111/j.0006-341X.2000.00455.x

30. Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

31. Petersen RA, Brown SP. On the use of beta coefficients in meta-analysis. Biometrics. 1994;50:1088–1101

32. Gamaldo AA, Weatherbee SR, Allaire JC. Exploring the within-person coupling of blood pressure and cognition in elders. J Gerontol B Psychol Sci Soc. 2000;56:455–463. doi: 10.1111/j.0006-341X.2000.00455.x

33. Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008

34. Santos WB, Matoso JM, Maltez M, Gonçalves T, Casanova M, Moreira IF, Lourenço RA, Monteiro WD, Farinatti PT, Soares PR, et al. Spectral analyses of systolic blood pressure and heart rate variability and their association with cognitive performance in elderly hypertensive subjects. J Hum Hypertens. 2015;29:488–494. doi: 10.1038/jhh.2014.119

None.

Disclosures

None.
35. Yamamoto Y, Aikuchi I, Owai K, Hayashi M, Inami K. Twenty-four-hour blood pressure changes in the course of lacunar disease. Cerebrovasc Dis 2001;11:100–106. doi:10.1159/000047620

36. Cicconetti P, Monteforte G, Thau F, Lorio A, Durante M, Piccirillo G, Cacciafiesta M, Mariigiano V. Cognitive assessment in the elderly with new mild systolic hypertension. Arch Gerontol Geriatr. 1998;Suppl 63:75–78

37. Elifonova NY, Chernov VI, Elifonova IV, Lishmanov YB. Influence of antihypertensive therapy on cerebral perfusion in patients with metabolic syndrome, relationship with cognitive function and 24-hour arterial blood pressure monitoring. Cardiovasc Ther. 2015;33:209–215. doi:10.1111/1575-9922.12136

38. Halkivi RJ, Foley DJ, Sayer B, Masaki K, White L, Launer LJ. Variability in midlife systolic blood pressure is related to late-life brain white matter lesions: the Honolulu-Asia Aging study. Stroke. 2002;33:226–30. doi:10.1161/01.STR.33.1.226

39. Kilander L, Nyman H, Boberg M, Hansson L, Litthell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31:780–786. doi:10.1161/01.hyp.31.5.780

40. Mossello E, Pieraccioni MC, Zanieri S, Fedeli A, Belladonna M, Nesti N, Marchionni N, Masotti G, Ungar A. Ambulatory blood pressure monitoring in older nursing home residents: diagnostic and prognostic role. J Am Med Dir Assoc. 2012;13:760.e1–760.e5. doi:10.1016/j.jamda.2012.05.017

41. Ramírez AJ, Parati G, Castiglioni P, Consalvo D, Solis P, Risk MR, Waissman P, di Renzo M, Mancia G, Sanchez RA. Elderly hypertensive patients: silent white matter lesions, blood pressure variability, baroreflex impairment, and cognitive deterioration. Curr Hypertens Rev. 2011;7:80–87.

42. Yaneya-Sirakova T, Traykov L, Petrova J, Gruve I, Vassileva D. Screening for cognitive impairment in children and adolescents in the urban and rural school setting of Bulgaria. Neurosci Lett. 2019;711:109365. doi:10.1016/j.neulet.2019.109365

43. Dore GA, Elia MF, Crichton GE, Robbins MA. Age modifies the relation of hyperglycemia, insulin resistance, and blood pressure in diabetes-associated differences in cognitive performance - the Maastricht Study. Diab Care. 2017;40:1537–1547

44. Gunstad J, Keary TA, Spitznagel MB, Poppas A, Paul RH, Sweet LH, Furth SL. Neurocognitive dysfunction in children, adolescents, and young adults with CKD. Am J Kidney Dis. 2015;66:549–557. doi:10.1053/j.ajkd.2015.08.025

45. Ramírez AJ, Parati G, Castiglioni P, Consalvo D, Solis P, Risk MR, Waissman P, di Renzo M, Mancia G, Sanchez RA. Elderly hypertensive patients: silent white matter lesions, blood pressure variability, baroreflex impairment, and cognitive deterioration. Curr Hypertens Rev. 2011;7:80–87.

46. Sepulveda LC, Sep SJ, Celessens D, Schram MT, Van Bostel MP, Henny RMA, Verhey FRJ, Kroon AA, Dagnelie PC, Schalkwijk CG, et al. The role of hyperglycemia, insulin resistance, and blood pressure in diabetes-associated differences in cognitive performance - the Maastricht Study. Diab Care. 2017;40:1537–1547

47. Lee SH, Han K, Cho H, Park YM, Kwon HS, Kang G, Yoon KH, Kim MK. Variability in metabolic parameters and risk of dementia: a nationwide population-based study. Alzheimers Res Ther. 2018;10:110. doi:10.1186/s13195-018-0442-3

48. Nagai M, Hoshide S, Nishikawa M, Masahisa S, Kario K. Visit-to-visit blood pressure variability in the elderly: associations with cognitive impairment and carotid artery remodeling. Atherosclerosis. 2014;234:19–26. doi:10.1016/j.atherosclerosis.2013.11.071

49. Yamaguchi Y, Wada M, Sato H, Nagasawa H, Koyama T, Hara A, Hirose T, Obara T, et al. Day-to-day variability in home blood pressure is associated with cognitive decline: the Ohasama study. Hypertension. 2014;63:1333–1338. doi:10.1161/HYPERTENSIONAHA.113.01819

50. Matsumoto C, Ogawa H, Saito Y, Okada S, Sakuma M, Soejima H, Nakayama M, Doi N, Jinnouchi H, Waki M, et al. The association of visit-to-visit blood pressure variability and cognitive decline in very elderly patients with type 2 diabetes: KAMOGAWA-HBP study. J Hypertens. 2019;17:560–567. doi:10.1016/j.jhype.2019.02.005

51. Doi N, Jinnouchi H, Waki M, et al. The association of visit-to-visit blood pressure variability and cognitive decline in very elderly patients with type 2 diabetes: KAMOGAWA-HBP study. J Hypertens. 2019;17:560–567. doi:10.1016/j.jhype.2019.02.005

52. Alpérovitch A, Blachier M, Soumaré A, Ritchie K, Dartigues JF, Richard E. Visit-to-visit blood pressure variability and risk of dementia in a General Japanese Elderly Population: The Hisayama Study. Hypertension. 2017;13:651–661. doi:10.1161/HYPERTENSIONAHA.113.01819

53. Böhm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, Schmieder R, Schmieder R, Schmieder R. Blood pressure variability predicts cognitive decline in Alzheimer’s disease patients. Neurobiol Aging. 2014;35:2282–2287. doi:10.1016/j.neurobiolaging.2014.04.022

54. Ma Y, Wolters FJ, Chibnall LB, Slicher S, Ikram MA, Hofman A, Ijzermans J. The association of visit-to-visit blood pressure variability and cognitive decline in older people: a 5-year longitudinal study. J Hypertens. 2017;35:140–147. doi:10.1093/HTJ/HJX000000000001120

55. Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure variability: new independent determinants for cognitive function in the elderly at high risk of cardiovascular disease. J Hypertens. 2012;30:1556–1563. doi:10.1016/j.jhype.2013.02.028

56. Oishi E, Ohara T, Sakata S, Fukuhara M, Hata J, Yoshida D, Shibata M, Ohtsubo T, Kitazono T, Kikuya Y, et al. Day-to-day blood pressure variability and risk of dementia in a General Japanese Elderly Population: The Hisayama Study. Hypertension. 2017;13:651–656. doi:10.1161/HYPERTENSIONAHA.116.1292667

57. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poullier R, Ma S, et al; HYVET investigators. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo-controlled trial. Lancet. 2008;371:683–689. doi:10.1016/S1474-4422(08)70141-1

58. Roush L, Cestac F, Sallier B, Benattar-Zbi L, Bertin P, Berent G, Coruble E, Deumeaux G, Falissard B, Forette F, et al. Visit-to-visit blood pressure variability is associated with cognitive decline and incident dementia: The SAGES cohort. Circ. 2019;140

59. Sakakura K, Ishikawa J, Okuno M, Shimada K, Kario K. Exaggerated ambulatory blood pressure variability is associated with cognitive dysfunction in the very elderly and quality of life in the younger elderly. Am J Hypertens. 2007;20:720–727. doi:10.1016/j.amjhyt.2007.02.001

60. van Middelbaar T, van Dalen JW, van Gool WA, van den Born BH, van Vught LA, Moll van Charante EP, Richard E. Visit-to-visit blood pressure variability and the risk of dementia in older people. J Alzheimers Dis. 2018;62:727–735. doi:10.3233/JAD-170757

61. Yamaguchi Y, Wada M, Sato H, Nagasawa H, Koyama T, Kato T. Impact of nocturnal blood pressure variability on cerebral small vessel disease progression and cognitive decline in community-based elderly Japanese. Am J Hypertens. 2014;27:1257–1267. doi:10.1039/jhuph/2014

62. Yun JE, Shin DW, Han K, Kim D, Lee SP, Jeong SM, Lee J, Kim S. Blood Pressure variability and the risk of dementia: A Nationwide Cohort Study. Hypertension. 2020;75:982–990. doi:10.1161/HYPERTENSIONAHA.119.14033
72. Van Middelaar T, Van Dalen JW, Van Gool WA, Moll Van Charante EP, Richard E. The association between visit-to-visit blood pressure variability and cognitive impairment in older people. Eur Stroke J. 2016;1:242.

73. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2006;300:1234–1241. doi: 10.1001/jama.2006.0923

74. Chuang SY, Hsu PF, Chang HY, Bai CH, Yeh WT, Pan HW. C-reactive protein predicts systolic blood pressure and pulse pressure but not diastolic blood pressure: the Cardiovascular Disease Risk Factors Two-Township Study. Am J Hypertens. 2013;26:657–664. doi: 10.1093/ajh/hps095

75. Matsumoto C, Ogawa H, Saito Y, Okada S, Soejima H, Sakuma M, Masuda I, Nakayama M, Doi N, Jinnouchi H, et al. JPAD Trial Investigators. Sex difference in effects of low-dose aspirin on prevention of dementia in patients with type 2 diabetes: a long-term follow-up study of a randomized clinical trial. Diabetes Care. 2020;43:314–320. doi: 10.2337/dc19-1188

76. Baranowski J, Klarch K, Sadowski M, Wiedeka K. The association between cognitive decline and short-term blood pressure variability in middle-aged patients with primary hypertension - a pilot study. Arterial Hypertens (Poland). 2018;22:135–142. doi: 10.5603/AHA2018.0013

77. Bellelli G, Pezzi A, Bianchetti A, Trabucchi M. Increased blood pressure variability may be associated with cognitive decline in hypertensive elderly subjects with no dementia. Arch Intern Med. 2002;162:483–484. doi: 10.1001/archinte.162.4.483

78. Chen C, Lee J, Kim JY, Lee C, Chang Y. Low diastolic blood pressure and high blood pressure variability are risk factors for cognitive decline in elderly adults: a case-control study. Neuropsychiatry. 2018;18:1986–1992.

79. Cho N, Hoshide S, Nishizawa M, Fujiwara T, Kario K. Relationship between blood pressure variability and cognitive function in elderly patients with good blood pressure control. Am J Hypertens. 2018;31:293–298. doi: 10.1093/ajh/hpx155

80. Cicconetti P, Costarella M, Moisè A, Ciotti V, Tafaro L, Monteforte G, Piccirillo G, Cacciapfesta M. Blood pressure variability and cognitive function in older hypertensives. Arch Gerontol Geriatr Suppl. 2004;38:63–68.

81. Cohen RA, Poppas A, Forman DE, Hoth KF, Haley AP, Piccirillo G, Cacciafesta M. Blood pressure variability and cognitive function among Older African Americans: a case-control study. J Clin Exp Neuropsychol. 2009;31:96–110. doi: 10.1080/13803390802014594

82. Conway KS, Forbang N, Beben T, Criqui MH, Hj JH, Ritkin DE. Relationship between 24-hour ambulatory blood pressure and cognitive function in community-living older adults: the UCSD ambulatory blood pressure study. Am J Hypertens. 2015;28:1444–1452. doi: 10.1093/ajh/hpv042

83. Crichton GE, Elias MF, Gore GA, Torres RV, Robbins MA. Measurement-to-measurement blood pressure variability is related to cognitive performance: the Maine Syracuse study. Hypertension. 2014;64:1094–1101. doi: 10.1161/HYPERTENSIONAHA.114.04282

84. Epstein NU, Lane KA, Farlow MR, Risacher SL, Saykin AJ, Gao S. Cognitive dysfunction and greater visit-to-visit systolic blood pressure variability. J Am Geriatr Soc. 2013;61:2168–2173. doi: 10.1111/jgs.12542

85. Fioravanti M, Nacca D, Gollferi B, Lucia P, Cugini P. The relevance of continuous blood pressure monitoring in examining the relationship of memory efficiency with blood pressure characteristics. Physiol Behav. 1996;65:1077–1084. doi: 10.1016/0031-9384(96)00259-7

86. Gódi K, Kabayama M, Gondo Y, Yasumoto S, Sekiguchi T, Noma T, Tanaka K, Koyoshige E, Akagi Y, Sugimoto K, et al. Day-to-day blood pressure variability is associated with lower cognitive performance among the Japanese community-dwelling oldest-old population: The SONIC study. Hypertens Res. 2020;43:404–411.

87. Goldstein IB, Shapiro D, La Rue A, Guthrie D. Relationship between 24-hour ambulatory blood pressure and cognitive function in healthy elderly people. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 1998;5:215–224. doi: 10.1076/ndcb.5.3.215611

88. Haring B, Liu J, Salmoiraghi-Blotcher E, Hayden KM, Sarto G, Rousou J, Rasp SR, Wassertheil-Smoller S. Blood pressure variability and brain morphology in elderly women without cardiovascular disease. Neurology. 2019;92:e1284–e1297. doi: 10.1212/WNL.0000000000007135

89. Kanemaru A, Kanemaru K, Kuwajima I. The effects of short-term blood pressure variability and nighttime blood pressure levels on cognitive function. Hypertens Res. 2001;24:19–24. doi: 10.1291/hiyres.24.19
variability is associated with lower cognitive performance. Hypertension. 2019;73:803–811. doi: 10.1161/HYPERTENSIONAHA.118.12305

108. Rawlings AM, Juraschek SP, Heiss G, Hughes T, Meyer ML, Selvin E, Sharrett AR, Windham BG, Gottesman RF. Association of orthostatic hypotension with incident dementia, stroke, and cognitive decline. Neurology. 2018;91:e759–e768. doi: 10.1212/WNL.0000000000006027

109. de Courson H, Leffondré K, Tzourio C. Blood pressure variability and risk of cardiovascular event: is it appropriate to use the future for predicting the present? Eur Heart J. 2018;39:4220. doi: 10.1093/eurheartj/ehy825

110. Landau SM, Harrison TM. A link between cardiovascular risk management and Alzheimer disease is still elusive. JAMA Neurol. 2021;78:524–526. doi: 10.1001/jamaneurol.2021.0083

111. Nagai M, Hoshide S, Kario K. The insular cortex and cardiovascular system: a new insight into the brain-heart axis. J Am Soc Hypertens. 2010;4:174–182. doi: 10.1016/j.jash.2010.05.001

112. de Heus RAA, de Jong DLK, Sanders ML, van Spijker GJ, Oudegeest-Sander MH, Hopman MT, Lawlor BA, Olde Rikkert MGM, Claassen JAHR. Dynamic regulation of cerebral blood flow in patients with Alzheimer disease. Hypertension. 2018;72:139–150. doi: 10.1161/HYPERTENSIONAHA.118.10900

113. Azarpazhooh MR, Avan A, Cipriano LE, Munoz DG, Sposato LA, Hachinski V. Concomitant vascular and neurodegenerative pathologies double the risk of dementia. Alzheimers Dement. 2018;14:148–156. doi: 10.1016/j.jalz.2017.07.755

114. Parati G, Ochoa JE, Lombardi C, Bilo G. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013;10:143–155. doi: 10.1038/nrcardio.2013.1

115. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4:487–499. doi: 10.1016/S1474-4422(05)70141-1